Vicore Pharma Holding AB
STO:VICO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.9665
23.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vicore Pharma Holding AB
PP&E Net
Vicore Pharma Holding AB
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Vicore Pharma Holding AB
STO:VICO
|
PP&E Net
kr10k
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
||
Biogaia AB
STO:BIOG B
|
PP&E Net
kr213.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
||
Bonesupport Holding AB
STO:BONEX
|
PP&E Net
kr20.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
||
Vitrolife AB
STO:VITR
|
PP&E Net
kr391m
|
CAGR 3-Years
35%
|
CAGR 5-Years
17%
|
CAGR 10-Years
16%
|
||
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
PP&E Net
kr384m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
13%
|
||
BioArctic AB
STO:BIOA B
|
PP&E Net
kr31.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
Vicore Pharma Holding AB
Glance View
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.
See Also
What is Vicore Pharma Holding AB's PP&E Net?
PP&E Net
10k
SEK
Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's PP&E Net amounts to 10k SEK.
What is Vicore Pharma Holding AB's PP&E Net growth rate?
PP&E Net CAGR 5Y
-53%
Over the last year, the PP&E Net growth was -74%. The average annual PP&E Net growth rates for Vicore Pharma Holding AB have been -74% over the past three years , -53% over the past five years .